the aid library

LIST OPTIONS

Filter

3416

Operational manual on leishmaniasis vector control, surveillance, monitoring and evaluation

World Health Organisation (WHO) (2023) C_WHO

Despite the significant role of vector control in national leishmaniasis control programmes, the programmatic community perceives vector control as the weakest component of leishmaniasis control strategies in terms of resources, scientific evidence of the usefulness of interventions and capacity for... more

Download (181)

View PDF (214)

Human and dog rabies prevention and control

World Health Organization WHO; Bill & Melinda Gates Foundation (2009) C_WHO

Report of the WHO/Bill & Melinda Gates Foundation Consultation. The Consultation was organized back-to-back with the first annual meeting of the International Coordinating Group of the BMGF-funded project for human and dog rabies elimination in developing countries, held at WHO headquarters, Geneva,... more

External Link

Global report on neglected tropical diseases 2023

World Health Organisation (WHO) (2023) C_WHO

The World Health Organization (WHO) and the global community of countries, partners, donors, technical experts, scientists and field implementation teams continue to work towards the ultimate goal of a world free of the burden of neglected tropical ... more

Download (122)

View PDF (149)

SYRIAN ARAB REPUBLIC response to earthquake: Situation report #3

World Health Organisation (WHO) (2023) C_WHO

In the early morning of 6 February 2023, a magnitude 7.8 earthquake struck southern Türkiye near the northern border of Syria. The earthquake was followed 11 minutes later by a magnitude 6.7 aftershock. Many aftershocks continue to be felt across the region. Whilst the impact is still being ass... more

Download (140)

View PDF (160)

SYRIAN ARAB REPUBLIC response to earthquake: Situation report #2

World Health Organisation (WHO) (2023) C_WHO

In the early morning of 6 February 2023, a magnitude 7.8 earthquake occurred in southern Türkiye near the northern border of Syria. The earthquake was followed 11 minutes later by a magnitude 6.7 aftershock. Many aftershocks are still being felt across the region. Whilst the impact is still bei... more

WHO's response to the Ukraine crisis

World Health Organisation (WHO) (2023) C_WHO

Since 24 February 2022, the war in Ukraine has caused widespread suffering to its people and serious damage to the country’s infrastructure. Attacks on the country’s health system and its power network threaten people, compromise the provision ... more

External Link

Report of a global meeting on yaws eradication surveillance, monitoring and evaluation: Geneva, 29–30 January 2018

World Health Organization WHO; Institutional research information sharing iris (2018) C_WHO

Report of a global meeting on yaws eradication surveillance, monitoring and evaluation: Geneva, 29–30 January 2018. World Health Organization.

Download (143)

View PDF (196)

Global elimination of dog-mediated human rabies. Report

World Health Organization (WHO) (2016) C_WHO

Rabies remains an under-reported neglected zoonosis with a case-fatality rate of almost 100% in humans and animals. Dog-mediated human rabies causes tens of thousands of human deaths annually despite being 100% preventable. More than 95% of human cases are caused by the bite of a rabies-infected dog... more

Вывести из забвения для достижения. Целей в области устойчивого развития Механизм мониторинга и оценки прогресса для д орожной карты по борьбе с забытыми тропическими болезнями на 2021–2030 гг

World Health Organization WHO (2021) C_WHO

В дорожной карте по борьбе с забытыми тропическими болезнями на 2021–2030 гг. («дорожная карта») определены глобальные цели и основные этапы в отношении борьбы с 20 бол�... more

WHO's Response to the Ukraine Crisis. Interim Report. February to June 2022

World Health Organization (WHO) (2022) C_WHO

The military offensive by the Russian Federation in Ukraine which began February 2022 has triggered one of the world’s fastest-growing displacement and humanitarian crisis, with geopolitical and economic ripples felt across the globe. The ongoing war has caused large-scale disruptions to the deliv... more

User manual for WHO cervical cancer prevention and control costing tool: HPV vaccination module (‎C4P-HPV tool)

World Health Organisation (WHO) (2023) C_WHO

Cervical cancer is the fourth most common cancer in women worldwide in 2018, with 570,000 new cases and 311,000 deaths occurring annually.T he highest incidence rates are in Southern Africa, Eastern Africa, SubSaharan Africa, Western Africa, Melanesia, and Middle Africa . It also ranks as the leadin... more

Download (133)

View PDF (273)

WHO Sierra Leone Country Cooperation Strategy 2022–2025

World Health Organisation (WHO) (2023) C_WHO

The Country Cooperation Strategy is the World Health Organization’s corporate framework developed in response to a country’s needs and priorities. The 2022–2025 CCS is the fourth for WHO in Sierra Leone. It is a medium-term strategic document ... more

Download (142)

View PDF (164)

Morbidity management and disability prevention in lymphatic filariasis

World Health Organization (WHO) (2013) C_WHO

The content of these guidelines goes beyond the technicalities of medical needs with additional insights into community empowerment, possible access to welfare and economic opportunities and similar issues. If these are adequately explored, the health... more

WHO mid-term programmatic and financial report for 2016-2017 including audited financial statements for 2016

World Health Organisation (WHO) (2017) C_WHO

In an ambitious new era for health development under the 2030 Agenda for Sustainable Development, WHO and its partners have a solid foundation of success on which to build. Health plays a fundament... more

Download (290)

View PDF (386)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (162)

View PDF (321)

Guidelines for drinking-water quality: Small water supplies

World Health Organization WHO (2024) C_WHO

Small drinking-water supplies commonly experience operational, managerial, technical and resourcing challenges that impact their ability to deliver safe and reliable services. The needs and opportunities associated with these supplies therefore warrant explicit consideration in policies and regulati... more

Prevention, Screening and Control of Common Non-Communicable Diseases: Hypertension, Diabetes an Common Cancers (Oral, Breast, Cervix)

National Health Mission (2016) CC

Comprehensive Primary Health Care has an important role in the primary and secondary prevention of several disease conditions, including non-communicable diseases which today contribute to over 60% of the mortality in India. The provision of Compreh... more

Sharing successful strategies from the Eastern Mediterranean Region in mitigating noncommunicable diseases and mentalhealth disorders during the COVID-19pandemic and beyond

World Health Organization (WHO) Regional Office for the Eastern Mediterranean World Health Organization (WHO) Regional Office for the Eastern Mediterranean (2023) C_WHO

The "Stories from the field" document by the WHO Regional Office for the Eastern Mediterranean shares effective strategies from the Eastern Mediterranean Region for addressing noncommunicable diseases (NCDs) and mental health challenges, particularl... more

WHO clinical consortium on healthy ageing 2023

World Health Organisation (WHO) (2024) C_WHO

The 2023 meeting of the WHO Clinical Consortium on Healthy Ageing (CCHA) was the group’s ninth gathering and took place in Geneva 5–7 December 2023. The meeting was structured around seven panels, with a series of technical presentations, plenary discussions and group work, and a final session o... more

Risk communication and community engagement readiness and response toolkit: zika virus

World Health Organisation (WHO) (2024) C_WHO

Toolkit regarding Zika Virus